Comparison between total thyroidectomy and medical therapy for amiodarone-induced thyrotoxicosis.

CONTEXT It is not known whether total thyroidectomy is more favourable than medical therapy for patients with amiodarone-induced thyrotoxicosis (AIT). OBJECTIVE To compare total thyroidectomy with medical therapy on survival and cardiac function in AIT patients. METHODS Observational longitudinal cohort study involving 207 AIT patients that had received total thyroidectomy (surgery group, n=51) or medical therapy (medical therapy group, n=156) over a 20-year period. AIT types and left ventricular ejection fraction (LVEF) classes were determined at diagnosis of AIT. Cardiac and thyroid function were re-evaluated during the study period. Survival was estimated using the Kaplan-Meier method. RESULTS Overall mortality and cardiac-specific mortality at 10 and 5 years, respectively, were lower in the surgery group than in the medical therapy group (p=0.04 and p=0.01, respectively). The lower mortality rate of the surgery group was due to patients with moderate-to-severely compromised LVEF (p=0.005 vs medical therapy group). In contrast, mortality of patients with normal or mildly-reduced LVEF did not differ between the two groups (p=0.281 and p=0.135, respectively). Death of patients with moderate-to-severe LV systolic dysfunction in the medical therapy group occurred after 82 days (IQR 56-99), a period longer than that necessary to restore euthyroidism in the surgery group (26 days, IQR 15-95; p=0.038). Risk factors for mortality were age (HR=1.036) and LVEF (HR=0.964), whereas total thyroidectomy was shown to be a protective factor (HR=0.210). LVEF increased in both groups after restoration of euthyroidism, above all in the most compromised patients in the surgery group. CONCLUSIONS Total thyroidectomy could be considered the therapeutic choice for AIT patients with severe systolic dysfunction, whereas it is not superior to medical therapy in those with normal or mildly-reduced LVEF.

[1]  G. Thompson,et al.  Thyroidectomy for Amiodarone-Induced Thyrotoxicosis: Mayo Clinic Experience , 2018, Journal of the Endocrine Society.

[2]  Shangtong Lei Interpretation for surgical section of 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis , 2018 .

[3]  M. Vanderpump,et al.  2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction , 2018, European Thyroid Journal.

[4]  E. Christ,et al.  Total Thyroidectomy for Amiodarone-induced Thyrotoxicosis in the Hyperthyroid State. , 2015, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[5]  R. Mariotti,et al.  Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. , 2012, The Journal of clinical endocrinology and metabolism.

[6]  C. Pierret,et al.  Total thyroidectomy for amiodarone-associated thyrotoxicosis: should surgery always be delayed for pre-operative medical preparation? , 2012, The Journal of Laryngology & Otology.

[7]  Elena S. Di Martino,et al.  Amiodarone and the thyroid: A 2012 update , 2012, Journal of Endocrinological Investigation.

[8]  L. Hegedüs,et al.  A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. , 2011, European journal of endocrinology.

[9]  F. Bogazzi,et al.  Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study. , 2011, The Journal of clinical endocrinology and metabolism.

[10]  F. Bogazzi,et al.  Approach to the patient with amiodarone-induced thyrotoxicosis. , 2010, The Journal of clinical endocrinology and metabolism.

[11]  D. Conen,et al.  Amiodarone-induced thyrotoxicosis: clinical course and predictors of outcome. , 2007, Journal of the American College of Cardiology.

[12]  P. Miccoli,et al.  One-Day Thyroid Surgery: Retrospective Analysis of Safety and Patient Satisfaction on a Consecutive Series of 1,571 Cases over a Three-Year Period , 2007, European Surgical Research.

[13]  F. Bogazzi,et al.  Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. , 2007, The Journal of clinical endocrinology and metabolism.

[14]  I. Gough,et al.  Total Thyroidectomy for Amiodarone-associated Thyrotoxicosis in Patients with Severe Cardiac Disease , 2006, World Journal of Surgery.

[15]  A. O’Sullivan,et al.  Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. , 2006, European journal of endocrinology.

[16]  D. Farley,et al.  Surgical Management of Amiodarone-associated Thyrotoxicosis: Mayo Clinic Experience , 2004, World Journal of Surgery.

[17]  D. Levy,et al.  Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the Community , 2003, Circulation.

[18]  A. Pinchera,et al.  Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis , 2003, Journal of endocrinological investigation.

[19]  A. Pinchera,et al.  Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone-induced thyrotoxicosis before thyroidectomy. , 2002, Surgery.

[20]  M. Irwin,et al.  The ASA Physical Status Classification: Inter-observer Consistency , 2002, Anaesthesia and intensive care.

[21]  A. Pinchera,et al.  Iopanoic acid rapidly controls Type I amiodarone-induced thyrotoxicosis prior to thyroidectomy , 2002, Journal of endocrinological investigation.

[22]  L. Braverman,et al.  The various effects of amiodarone on thyroid function. , 2001, Thyroid : official journal of the American Thyroid Association.

[23]  L. Braverman,et al.  The effects of amiodarone on the thyroid. , 2001, Endocrine reviews.

[24]  C. Bartolozzi,et al.  Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. , 1997, Thyroid : official journal of the American Thyroid Association.

[25]  T. Rago,et al.  Color flow doppler sonography in thyrotoxicosis factitia , 1996, Journal of endocrinological investigation.

[26]  C. Siu,et al.  Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. , 2009, The Journal of clinical endocrinology and metabolism.

[27]  A. Pinchera,et al.  Minimally Invasive Video-Assisted Thyroidectomy Surgical Treatment of Low-and Intermediate-Risk Papillary Thyroid Cancer , 2009 .

[28]  W. Wiersinga Amiodarone and the thyroid , 1997 .